Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane-based induction chemotherapy and concurrent chemo-radiotherapy in the modern era.
Clinical outcomes
Induction chemotherapy and intensity-modulated radiotherapy
Intracranial extension
Nasopharyngeal cancer
Journal
World journal of otorhinolaryngology - head and neck surgery
ISSN: 2589-1081
Titre abrégé: World J Otorhinolaryngol Head Neck Surg
Pays: United States
ID NLM: 101690857
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
26
06
2019
revised:
20
02
2020
accepted:
27
02
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
To evaluate the survival outcomes for a cohort of nasopharyngeal cancer with intracranial extension (ICE) treated with induction chemotherapy (ICT) followed by chemo-intensity-modulated radiotherapy (CTRT) at a tertiary cancer center. We retrospectively analyzed 45 patients with histologically proven, non-metastatic NPC with ICE treated at our institute between October 2008 and October 2016. Patients were classified as minor ICE or major ICE, based on the extent of ICE. All the patients received 2-3 cycles of a taxane-based ICT regimen followed by CTRT. Radiotherapy was delivered with "risk-adapted" intensity-modulated radiotherapy (IMRT) technique in all patients. After a median follow up of 45 months (range: 8-113 months), the estimated 5-year DFS, LRFS, DMFS, and OS of the entire cohort was 58%, 82%, 67% and 74% respectively. On multivariate analysis, histological subtype was an independent predictor of LRFS, and age was an independent predictor of DFS. The extent of ICE showed only a trend towards worse DFS ( Taxane-based induction chemotherapy followed by chemo-intensity modulated radiotherapy resulted in excellent locoregional control and survival with acceptable toxicities in patients of nasopharyngeal cancer with intracranial extension. Distant metastasis continues to be the predominant problem in these patients.
Identifiants
pubmed: 32426700
doi: 10.1016/j.wjorl.2020.02.003
pii: S2095-8811(20)30024-X
pmc: PMC7221210
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25-33Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Radiother Oncol. 2014 Mar;110(3):377-84
pubmed: 24630534
Radiother Oncol. 2012 Sep;104(3):343-8
pubmed: 22853852
Radiother Oncol. 2008 May;87(2):204-10
pubmed: 18329742
Int J Cancer. 2001 Apr 20;96(2):126-31
pubmed: 11291096
Radiat Oncol. 2013 Oct 02;8:226
pubmed: 24083351
Eur Arch Otorhinolaryngol. 2016 Aug;273(8):2209-15
pubmed: 26282900
J Clin Oncol. 2009 Jan 10;27(2):242-9
pubmed: 19064973
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):57-62
pubmed: 15936155
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56
pubmed: 16377415
Cancer Res Treat. 2017 Apr;49(2):518-525
pubmed: 27554478
Oncotarget. 2015 Sep 15;6(27):24511-21
pubmed: 26087194
Jpn J Clin Oncol. 2011 Jan;41(1):95-102
pubmed: 20852300
Clin Oncol (R Coll Radiol). 2019 Dec;31(12):850-857
pubmed: 31296457
Cancer. 2016 Feb 15;122(4):546-58
pubmed: 26588425
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):145-57
pubmed: 12694833
Radiother Oncol. 2012 Sep;104(3):286-93
pubmed: 22995588
J Natl Cancer Inst. 2005 Apr 6;97(7):536-9
pubmed: 15812080
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16
pubmed: 15752890
J Clin Oncol. 1998 Apr;16(4):1310-7
pubmed: 9552031
Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):794-9
pubmed: 12874084
Lancet Oncol. 2012 Feb;13(2):163-71
pubmed: 22154591
Lancet Oncol. 2015 Jun;16(6):645-55
pubmed: 25957714
Ann Oncol. 2012 Feb;23(2):427-35
pubmed: 21525406
Lancet Oncol. 2016 Nov;17(11):1509-1520
pubmed: 27686945
Oral Oncol. 2015 Feb;51(2):190-4
pubmed: 25434585
J Clin Oncol. 2005 Sep 20;23(27):6730-8
pubmed: 16170180